A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries

Shouki Bazarbashi, Wen Pin Su, Siew W. Wong, Ramanujam A. Singarachari, Sudhir Rawal, Maria I. Volkova, Diogo A. Bastos

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC.

Original languageEnglish
Pages (from-to)311-327
Number of pages17
JournalOncology and Therapy
Volume9
Issue number2
DOIs
Publication statusPublished - 2021 Dec

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint

Dive into the research topics of 'A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries'. Together they form a unique fingerprint.

Cite this